Effects of Shengmai Yin(生脉饮)on pulmonary and cardiac function in coronavirus disease 2019 convalescent patients with cardiopulmonary symptoms:a randomized,double blind,multicenter control trial  

作　　者：AN Xuedong MAO Lina XIA Ping SU Wen WANG Beibei KOU Leiya ZHANG Zequan QI Meng HU Song CHEN Jing LI Xiujuan LIU Jinwei ZHOU Juan QIAO Jie LUO Dan LUO Guangwei YAN Youqin YANG Guiping DONG Dandan ZHOU Wei TAO Junxiu JIN De TONG Xiaolin WEI Li 

机构地区：[1]Institute of Metabolic Diseases,Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China [2]Department of Traditional Chinese Medicine,Wuhan No.1 Hospital(Wuhan Integrated TCM and Western Medicine Hospital),Wuhan 430022,China [3]Department of Orthopedics,Wuhan No.1 Hospital(Wuhan Integrated TCM and Western Medicine Hospital),Wuhan 430022,China [4]Department of Paediatrics,Wuhan No.1 Hospital(Wuhan Integrated TCM and Western Medicine Hospital),Wuhan 430022,China [5]Department of Respiratory and Critical Care Medicine,Wuhan No.1 Hospital(Wuhan Integrated TCM and Western Medicine Hospital),Wuhan 430022,China [6]College of Traditional Chinese Medicine,Hubei University of Traditional Chinese Medicine,Wuhan430060,China [7]Department of Pharmacy,Wuhan No.1 Hospital(Wuhan Integrated TCM and Western Medicine Hospital),Wuhan 430022,China [8]Department of Geriatrics,Wuhan No.1 Hospital(Wuhan Integrated TCM and Western Medicine Hospital),Wuhan 430022,China [9]Department of Infectious Diseases,Wuhan No.7 Hospital,Wuhan 430071,China [10]Department of Gastroenterology,Xiaogan Traditional Chinese Medicine Hospital,Xiaogan 432100,China [11]Department of Gastroenterology,Wuhan No.7 Hospital,Wuhan 430071,China [12]Department of Hepatology,Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430061,China [13]Institute of Metabolic Diseases,Guang’an Men Hospital of China Academy of Chinese Medical Sciences,Beijing 100053,China [14]Department of Critical Care Medicine,Wuhan No.1 Hospital(Wuhan Integrated TCM and Western Medicine Hospital),Wuhan 430022.China

出　　处：《Journal of Traditional Chinese Medicine》2023年第1期140-145,共6页中医杂志（英文版）

基　　金：Supported by Randomized,Double-blind,Placebo-controlled,Multicenter Clinical Study to Improve Symptoms Associated with Pulmonary Heart Function during Recovery from COVID-19(II)(No.2020ZYLCYJ08-4)。

摘　　要：OBJECTIVE:To evaluate the efficacy and safety of Shengmai Yin(生脉饮,SMY)on visual analogue scale(VAS)for cardiopulmonary symptoms in coronavirus disease 2019(COVID-19)convalescent patients.METHODS:In this randomized,double blind and multicenter controlled trial,a total of 200 COVID-19 convalescent patients who with cardiopulmonary symptoms were enrolled from three medical centers in Hubei,China.These patients were randomized divided into trial group and the control group,100 patients in each one,SMY and its placebo were applied to respectively,for two weeks.VAS of clinical symptoms included shortness of breath,hidrosis,chest distress,palpitation,and dry cough was performed at 0,1,2 weeks.Decrease in VAS of 30%or more was defined as effective,and a reduction in VAS of 0 was defined as curative.RESULTS:A total of 192 completed the study.The VAS of TCM symptoms showed there was no difference in baseline between the two groups.The VAS in both groups was down-regulated,and there was no significant difference in VAS and cure rates at the first and second week between the two groups.There was no significant difference in breath,hidrosis,palpitation,and dry cough between the two groups but SMY treatment for two weeks has remarkable therapeutic effects in chest distress than placebo.CONCLUSIONS:SMY could effectively ameliorate the symptoms of chest distress,and improve the quality of life of the COVID-19 convalescent patients.

关 键 词：COVID-19 CONVALESCENCE visual analog scale cardiopulmonary symptoms Shengmai Yin 

分 类 号：R285.5[医药卫生—中药学]